Douglas Robinson
- Molecular Biology
- Oncology top 10%
- Pulmonary and Respiratory Medicine
- Cancer Research
- Endocrinology, Diabetes and Metabolism
- Co-authors
- Humphrey GardnerJason ChesneyKevin B. KimMichael ShiJohn M. KirkwoodGuy JérusalemMasakazu ToiFabrice André
- Topics
- HER2/EGFR in Cancer Research (4 papers)Chronic Lymphocytic Leukemia Research (3 papers)PI3K/AKT/mTOR signaling in cancer (3 papers)
- Partner nations
- United StatesFranceItaly
In The Last Decade
Douglas Robinson
13 papers receiving 472 citations
Peers
Comparison fields: 5 of 60
- Molecular Biology 255
- Oncology 236
- Pulmonary and Respiratory Medicine 196
- Cancer Research 110
- Endocrinology, Diabetes and Metabolism 67
Countries citing papers authored by Douglas Robinson
This map shows the geographic impact of Douglas Robinson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas Robinson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas Robinson more than expected).
Fields of papers citing papers by Douglas Robinson
This network shows the impact of papers produced by Douglas Robinson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas Robinson. The network helps show where Douglas Robinson may publish in the future.
Co-authorship network of co-authors of Douglas Robinson
This figure shows the co-authorship network connecting the top 25 collaborators of Douglas Robinson. A scholar is included among the top collaborators of Douglas Robinson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas Robinson. Douglas Robinson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 0 | |
| 3 | 4 | |
| 4 | 3 | |
| 5 | 50 | |
| 6 | 135 | |
| 7 | 0 | |
| 8 | 14 | |
| 9 | Evaluation of Everolimus (EVE) in HER2+ advanced breast cancer (BC) with activated PI3K/mTOR pathway : exploratory biomarker observations from the BOLERO-3 trial | 12 |
| 10 | 5 | |
| 11 | 9 | |
| 12 | 100 | |
| 13 | 137 | |
| 14 | Utility of cetuximab-cross reactive IgE as a predictive biomarker for cetuximab associated severe infusion reactions | 1 |
| 15 | 10 |
About Douglas Robinson
Douglas Robinson is a scholar working on Genetics, Cancer Research and Oncology, having authored 15 papers that have together received 481 indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (4 papers), Chronic Lymphocytic Leukemia Research (3 papers) and PI3K/AKT/mTOR signaling in cancer (3 papers). The work is most often cited by research in Oncology (236 citations), Cancer Research (110 citations) and Pulmonary and Respiratory Medicine (196 citations). Douglas Robinson has collaborated with scholars based in United States, France and Italy. Frequent co-authors include Humphrey Gardner, Jason Chesney, Kevin B. Kim, Michael Shi, John M. Kirkwood, Guy Jérusalem, Masakazu Toi, Fabrice André, Howard A. Burris and David Chen. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.